Market Overview

Illumina Reports Filing of New Patent Infringement Case Against Ariosa Diagnostics

Related ILMN
Illumina Reported Its Fastest Top-line Growth Since 2015
Benzinga's Top Upgrades, Downgrades For October 25, 2017
Illumina, Inc. 2017 Q3 - Results - Earnings Call Slides (Seeking Alpha)

Illumina (NASDAQ: ILMN) announced today that the company has filed a new patent infringement suit against Ariosa Diagnostics, Inc. Illumina is seeking all available remedies, including injunctive relief.

The new suit, filed in the U.S. District Court for the Northern District of California, is based on Ariosa's infringement of U.S. Patent No. 7,955,794, entitled “Multiplex Nucleic Acid Reactions.” The suit targets Ariosa's Harmony™ Prenatal Test, including its use of digital analysis of selected regions (DANSR) that, among other things, enables simultaneous quantification of hundreds of DNA loci.

Verinata Health, now a wholly owned subsidiary of Illumina, previously sued Ariosa for infringement of U.S. Patent No. 8,296,076 and U.S. Patent No. 8,318,430 in the U.S. District Court for the Northern District of California. The Court in that case issued a Claim Construction Order providing the Court's interpretation of the disputed patent terms which supports the position that Ariosa infringes those patents.

Illumina offers the verifi® non-invasive prenatal test (formerly offered by Verinata Health) in its CLIA-certified, CAP-accredited clinical services laboratory, to detect chromosome abnormalities and aberrations with improved resolution for consistent and dependable results. verifi® is the broadest non-invasive prenatal test available today and is part of Illumina's comprehensive reproductive and genetic health portfolio.

Posted-In: News Legal Press Releases


Related Articles (ILMN)

View Comments and Join the Discussion!

Partner Center